Antitumor Effects of Epidermal Growth Factor Receptor Antisense Oligonucleotides in Combination with Docetaxel in Squamous Cell Carcinoma of the Head and Neck

Clinical Cancer Research

Volumn 9, Issue 13, 2003, Pages 5028-5035

  Niwa, Hideo ^a   Wentzel, Abbey L ^a   Li, Mengfeng ^a   Gooding, William E ^b   Lui, Vivian Wai Yan ^a   Grandis, Jennifer Rubin ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTISENSE OLIGONUCLEOTIDE; PHOSPHOTYROSINE; PROTEIN KINASE B; STAT3 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MIXTURE; DRUG POTENTIATION; DRUG TOXICITY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IC 50; MONOTHERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL LINE, TUMOR; COLORING AGENTS; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHOTYROSINE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TAXOIDS; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS; TRANS-ACTIVATORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0142250356     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Grandis, J. R., Melhem, M. F., Gooding, W. E., Holst, V. A., Wagener, M. M., Drenning, S. D., Tweardy, D. J. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst. (Bethesda), 90: 824-832, 1998.
2. Arteaga, C. L. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin. Oncol., 29: 3-9, 2002.
3. Shin, D. M., Donato, N. J., Perez-Soler, R., Shin, H. J., Wu, J. Y., Zhang, P., Lawhorn, K., Khuri, F. R., Glisson, B. S., Myers, J. et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res., 7: 1204-1213, 2001.
4. Robert, F., Ezekiel, M. P., Spencer, S. A., Meredith, R. F., Bonner, J. A., Khazaeli, M. B., Saleh, M. N., Carey, D., LoBuglio, A. F., Wheeler, R. H., et al. Phase 1 study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol., 19: 3234-3243, 2001.
5. Grandis, J. R., Chakraborty, A., Melhem, M. F., Zeng, Q., and Tweardy, D. J. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene, 15: 409-416, 1997.
6. Forastiere, A. A., and Urba, S. G. Experimental therapeutic approaches for recurrent head and neck cancer. Cancer Treat. Res., 74: 263-281, 1995.
7. Schoffski, P., Catimel, G., Planting, A. S., Droz, J. P., Verweij, J., Schrijvers, D., Gras, L., Schrijvers, A., Wanders, J., and Hanauske, A. R. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a Phase II study of the EORTC Early Clinical Studies Group. Ann. Oncol., 10: 119-122, 1999.
8. Posner, M. R. Docetaxel in squamous cell cancer of the head and neck. Anticancer Drugs, 12 (Suppl. 1): S21-S24, 2001.
9. Sacks, P. G., Parnes, S. M., Gallick, G. E., Mansouri, Z., Lichtner, R., Satya-Prakash, K. L., Pathak, S., and Parsons, D. F. Establishment and characterization of two new squamous cell carcinoma cell lines derived from tumors of the head and neck. Cancer Res., 48: 2858-2866, 1988.
10. Jetten, A. M., Kim, J. S., Sacks, P. G., Rearick, J. I., Lotan, R., Hong, W. K., and Lotan, R. Inhibition of growth and squamous cell differentiation markers in cultured human head and neck squamous carcinoma cells by b-all-trans-retinoic acid. Int. J. Cancer, 45: 195-202, 1990.
11. Yokoi, T., Yamaguchi, T., Odajima, J., and Furukawa, K. Establishment and characterization of a human cell line derived from a squamous cell carcinoma of the tongue. Tumor Res., 23: 43-57, 1988.
12. Witters, L., Kumar, R., Mandal, M., Bennett, C. F., Miraglia, L., and Lipton, A. Antisense oligonucleotides to the epidermal growth factor receptor. Breast Cancer Res. Treat., 53: 41-50, 1999.
13. Wang, S., Lee, R. J., Cauchon, G., Gorenstein, D. G., and Low, P. S. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. USA, 92: 3318-3322, 1995.
14. Lavelle, F., Bissery, M. C., Combeau, C., Riou, J. F., Vrignaud, P., and Andre, S. Preclinical evaluation of docetaxel (Taxotere). Semin. Oncol., 22: 3-16, 1995.
15. He, Y., Zeng, Q., Drenning, S. D., et al. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J. Natl. Cancer Inst. (Bethesda), 90: 1080-1087, 1998.
16. Albanell, J., Codony-Servat, J., Rojo, F., et al. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor α expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res., 61: 6500-6510, 2001.
17. Grandis, J. R., Drenning, S. D., Chakraborty, A., et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J. Clin. Investig., 102: 1385-1392, 1998.
18. Bancroft, C. C., Chen, Z., Yeh, J., et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int. J. Cancer, 99: 538-548, 2002.
19. Tolcher, A. W. Novel compounds in the therapy of breast cancer: opportunities for integration with docetaxel. Oncologist, 6 (Suppl. 3): 40-44, 2001.
20. Grandis, J. R., Zeng, Q., and Drenning, S. D. Epidermal growth factor receptor-mediated stat3 signaling blocks apoptosis in head and neck cancer. Laryngoscope, 110: 868-874, 2000.
21. Grandis, J. R., Drenning, S. D., Zeng, Q., Watkins, S. C., Melhem, M. F., Endo, S., Johnson, D. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Natl. Acad. Sci. USA, 97: 4227-4232, 2000.
22. Liu, T., Chen, J., and Zeng, C. Effects of antisense epidermal growth factor and its receptor retroviral expression vectors on cell growth of human pancreatic carcinoma cell line. Chin. Med. J. (Engl.), 108: 653-659, 1995.
23. Rubenstein, M., Mirochnik, Y., Ray, V., and Guinan, P. Lack of toxicity associated with the systemic administration of antisense oligonucleotides for treatment of rats bearing LNCaP prostate tumors. Med. Oncol., 14: 131-136, 1997.
24. Hirao, T., Sawada, H., Koyama, F., Watanabe, A., Yamada, Y., Sakaguchi, T., Tatsumi, M., Fujimoto, H., Emoto, K., Nariko, M., and et al. Antisense epidermal growth factor receptor delivered by adenoviral vector blocks tumor growth in human gastric cancer. Cancer Gene Ther., 6: 423-427, 1999.
25. Morris, M. J., Tong, W. P., Cordon-Cardo, C., Drobnjak, M., Kelly, W. K., Slovin, S. F., Terry, K. L., Siedlecki, K., Swason, P., Rafi, M., and et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res., 8: 679-683, 2002.
26. Waters, J. S., Webb, A., Cunningham, D., Clarke, P. A., Raynaud, F., di Stefano, F., and Cotter, F. E. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol., 18: 1812-1823, 2000.
27. Colevas, A. D., and Posner, M. R. Docetaxel in head and neck cancer: a review. Am. J. Clin. Oncol., 21: 482-486, 1998.
28. Colevas, A. D. Re: "Sialadenosis: a presenting sign in Bulemia" (Head and Neck, 20: 758-762, 1998). Head Neck, 21: 582, 1999.
29. Colevas, A. D. Re: "Sialadenosis: a presenting sign in Bulemia" (Head and Neck, 20: 758-762, 1998). Head Neck, 21: 582, 1999.
30. Couteau, C., Chouaki, N., Leyvraz, S., Oulid-Aissa, D., Lebecq, A., Domenge, C., Groult, V., Bordessoule, S., Janot, F., De Forni, M., and et al. A Phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br. J. Cancer, 81: 457-462, 1999.
31. Mason, K. A., Kishi, K., Hunter, N., Buchmiller, L., Akimoto, T., Komaki, R., and Milas, L. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin. Cancer Res., 5: 4191-4198, 1999.
32. Huttmann, C., Eckardt, A., Fokas, K., and Haindl, J. Experimental chemotherapy of xenotransplanted oral squamous epithelial carcinoma: effectiveness of docetaxel (taxotere) in the nude mouse model (in German). Mund Kiefer Gesichtschir, 3: 257-262, 1999.
33. Braakhuis, B. J., Kegel, A., and Welters, M. J. The growth inhibiting effect of docetaxel (Taxotere) in head and neck squamous cell carcinoma xenografts. Cancer Lett., 8: 151-154, 1994.
34. Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Pomatico, G., De Placido, S., Bianco, A. R., and Tortora, G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res., 6: 2053-2063, 2000.
35. Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Fontanini, G., Cuccato, S., De Placido, S., Bianco, A. R., and Tortora, G. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res., 7: 1459-1465, 2001.
36. Ranson, M., Hammond, L. A., Ferry, D., Kris, M., Tullo, A., Murray, P. I., Miller, V., Averbuch, S., Ochs, J., Morris, C., and et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a Phase I trial. J. Clin. Oncol., 20: 2240-2250, 2002.
37. Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I., and Kris, M. G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res., 6: 4885-4892, 2000.
38. Tortora, G., Caputo, R., Pomatico, G., Pepe, S., Bianco, A. R., Agrawal, S., Mendelsohn, J., and Ciardiello, F. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. Clin. Cancer Res., 5: 875-881, 1999.
39. Riedel, F., Gotte, K., Li. M., Hormann, K., and Grandis, J. R. EGFR antisense treatment of human HNSCC cell lines results in down-regulation of VEGF protein expression and endothelial cell migration. Int. J. Oncol., 21: 11-16, 2002.
40. Mendelsohn, J., and Fan, Z. Epidermal growth factor receptor family and chemosensitization. J. Natl. Cancer Inst. (Bethesda), 89: 341-343, 1997.